Fresenius Kabi announced the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira. IDACIO is available in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector).
“We are thrilled to launch IDACIO, our first immunology biosimilar in the U.S.,” said Ali Ahmed, senior vice president, Biosimilars at Fresenius Kabi USA. “Our adalimumab biosimilar forms part of a dedicated pipeline of affordable and high-quality immunology biosimilars from Fresenius Kabi, aimed to improve the quality of life of patients with chronic diseases.”
An IDACIO branded biosimilar is available in more than 35 countries. IDACIO (adalimumab-aacf) is indicated for reducing signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis in adults and plaque psoriasis.
The Centers for Medicare and Medicaid Services (CMS) issued a permanent product-specific Q-code for IDACIO (adalimumab-aacf). Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code assigned to IDACIO is effective for patients administered IDACIO on and after July 1, 2023. The new code for IDACIO is Q 5131.
To learn more about how Fresenius Kabi provides comprehensive patient support for IDACIO please click here.
IDACIO (adalimumab-aacf) is a tumor necrosis factor (TNF) blocker and a biosimilar to Humira (adalimumab). Adalimumab is a monoclonal antibody that binds TNFα and blocks its general cytokine effects. As a consequence, adalimumab modulates TNF-mediated cellular functions and is indicated for a range of autoimmune disorders.
Q-codes are permanent reimbursement codes granted to biosimilars and used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like IDACIO that are administered by a physician. Claims submission and documentation are simplified with a permanent Q-code, facilitating and streamlining the billing and reimbursement process.
SOURCE: Businesswire